"Phentermine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Below are MeSH descriptors whose meaning is more general than "Phentermine".
Below are MeSH descriptors whose meaning is more specific than "Phentermine".
This graph shows the total number of publications written about "Phentermine" by people in this website by year, and whether "Phentermine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Phentermine" by people in Profiles.
Wyne KL, Litwin SE, Cusi K, Guyton JR. JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. J Clin Lipidol. 2022 Mar-Apr; 16(2):115-127.
Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo D. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2021 11; 78(5):e38-e50.
McNeill S, Almallouhi E, Lowe FJ, Turan TN. Phentermine associated recurrent intracerebral hemorrhage. J Neurol Sci. 2018 10 15; 393:135-137.
Rebello CJ, Nikonova EV, Zhou S, Aronne LJ, Fujioka K, Garvey WT, Smith SR, Coulter AA, Greenway FL. Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). 2018 02; 26(2):332-339.
Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, Fujioka K, Aronne LJ. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 05; 25(5):857-865.
Guo F, Garvey WT. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, Troupin B, Day WW. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014 Apr; 37(4):912-21.
Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
Holes-Lewis KA, Malcolm R, O'Neil PM, Hermayer K. Pharmacotherapy of obesity: clinical treatments and considerations. Am J Med Sci. 2013 Apr; 345(4):284-288.